Research & Education
The Blood and Marrow Transplant (BMT) Program at Roswell Park Cancer Institute
The Blood and Marrow Transplant (BMT) program is dedicated to providing outstanding clinical care and conducting clinical trials related to novel approaches to BMT.
Read more about these outcomes.
The BMT Program treats selected patients with hematologic diseases including:
The BMT Program
The Roswell Park Cancer Institute (RPCI) Blood and Marrow Transplant (BMT) Program was established in 1991 and is certified by the National Marrow Donor Program as a Transplant, Collection and Apheresis Center.
The BMT team, under the direction of Philip McCarthy, MD offers both autologous (self-donated) and allogeneic (requiring a related or unrelated donor) transplantation of peripheral blood, bone marrow or cord blood. The RPCI program can offer BMT to patients aged 4 to 75 years.
The BMT program at RPCI offers a wide range of specialized transplant-related services including:
A unique aspect of our program is the presence of a clinical epidemiologist who monitors all BMT patient outcomes and oversees the BMT database. This attention to patient outcomes allows the program to make adjustments in clinical services to optimize patient care.
Since 2002, the program has had been certified through the Foundation for the Accreditation of Cellular Therapy (FACT). It emphasizes clinical trial development including investigator-initiated as well as cooperative group trials. The program continues to emphasize excellence in clinical care and patient outcomes.